Epidemiological characteristics of fatal Candida krusei fungemia in immunocompromised febrile neutropenic children

Infection

Volumn 36, Issue 1, 2008, Pages 88-91

  Agirbasli, H ^a   Otlu, B ^b   Bilgen, H ^c   Durmaz, R ^b   Gedikoglu, G ^a  

^a Pediatric Blood Diseases Hospital   (Turkey)

^b INONU UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIINFECTIVE AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; THYMOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIFUNGAL SUSCEPTIBILITY; BLOOD CULTURE; BLOOD FLOW; BODY TEMPERATURE; CANDIDA KRUSEI; CLINICAL TRIAL; DIAGNOSTIC TEST; DRUG DOSE INCREASE; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGEMIA; GRAFT FAILURE; HEALTH CARE PERSONNEL; HUMAN; INFECTION PREVENTION; LABORATORY TEST; LETTER; MOLECULAR TYPING; MORTALITY; PROSPECTIVE STUDY; PULSED FIELD GEL ELECTROPHORESIS;

ADOLESCENT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, FUNGAL; FEMALE; FEVER; FUNGEMIA; HUMANS; IMMUNOCOMPROMISED HOST; MALE; NEUTROPENIA;

EID: 43049168343     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-007-6246-1     Document Type: Letter

References (22)

1. Castagnola E, Cesaro S, Giacchino M, Livadiotti S, Tucci F, Zanazzo G, Caselli D, Caviglia I, Parodi S, Rondelli R, Cornelli PE, Mura R, Santoro N, Russo G, De Santis R, Buffardi S, Viscoli C, Haupt R, Rossi MR: Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J 2006; 25: 634-639.
2. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-1277.
3. Lopez-Ribot JL, McAtee RK, Kirkpatrick WR, Perea S, Patterson TF: Comparison of DNA-based typing methods to assess genetic diversity and relatedness among Candida albicans clinical isolates. Rev Iberoam Micol 2000; 17: 49-54.
4. Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J: Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant 2001; 28: 873-878.
5. Sobel JD: Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques. Pharmacotherapy 2006; 26: 47-54.
6. Bedini A, Venturelli C, Mussini C, Guaraldi G, Codeluppi M, Borghi V, Rumpianesi F, Barchiesi F, Esposito R: Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. Clin Microbiol Infect 2006; 12: 75-80.
7. Aquino VR, Lunardi LW, Goldani LZ, Barth AL: Prevalence, susceptibility profile for fluconazole and risk factors for candidemia in a tertiary care hospital in southern Brazil. Braz J Infect Dis 2005; 9: 411-418.
8. Hope W, Morton A, Eisen DP: Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 2002; 50: 56-65.
9. Jantunen E, Nihtinen A, Volin L, Juvonen E, Parkkali T, Ruutu T, Anttila VJ: Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis. Bone Marrow Transplant 2004; 34: 891-895.
10. Meunier F, Aoun M, Bitar N: Candidemia in immunocompromised patients. Clin Infect Dis 1992; 14: 120-125.
11. Moosa MY, Sobel JD: Non-albicans Candida infections in patients with hematologic malignancies. Semin Respir Infect 2002; 17: 91-98.
12. Swerdloff JN, Filler SG, Edwards JE Jr: Severe candidal infections in neutropenic patients. Clin Infect Dis 1993; 17: 457-467.
13. Sendid B, Cotteau A, Francois N, D'Haveloose A, Standaert A, Camus D, Poulain D: Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links. BMC Infect Dis 2006; 6: 80.
14. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S: The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122-1128.
15. Blot S, Janssens R, Claeys G, Hoste E, Buyle F, De Waele JJ, Peleman R, Vogelaers D, Vandewoude K: Effect of fluconazole consumption on long-term trends in candidal ecology. J Antimicrob Chemother 2006; 58: 474-477.
16. Krcmery V Jr, Mrazova M, Kunova A, Grey E, Mardiak J, Jurga L, Sabo A, Sufliarsky J, Sevcikova L, Sorkovska D, West D, Trupl J, Novotny J, Mateicka F: Nosocomial candidaemias due to species other than Candida albicans in cancer patients. Aetiology, risk factors, and outcome of 45 episodes within 10 years in a single cancer institution. Support Care Cancer 1999; 7: 428-431.
17. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT: Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
18. Wenzel RP: Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20: 1531-1534.
19. Vos MC, Endtz HP, Horst-Kreft D, Doorduijn J, Lugtenburg E, Verbrugh HA, Lowenberg B, de Marie S, van Pelt C, van Belkum A: Candida krusei transmission among hematology patients resolved by adapted antifungal prophylaxis and infection control measures. J Clin Microbiol 2006; 44: 1111-1114.
20. Becker K: Molecular biological differentiation of yeasts. Mycoses 2000; 43: 40-47.
21. Berrouane YF, Hollis RJ, Pfaller MA: Strain variation among and antifungal susceptibilities of isolates of Candida krusei. J Clin Microbiol 1996; 34: 1856-1858.
22. Saiman L, Ludington E, Pfaller M, Rangel-Frausto S, Wiblin RT, Dawson J, Blumberg HM, Patterson JE, Rinaldi M, Edwards JE, Wenzel RP, Jarvis W: Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000; 19: 319-324.